ReviewCureus2022
Systemic Lupus Erythematosus and Cardiovascular Disease.
Review in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Pooled it
- Anifrolumab Plus Standard of Care Reduces Long-Term Cardiovascular Damage in Adults With Systemic Lupus Erythematosus: Findings From a Real-World External Control Study.ACR open rheumatology · 2026Article
- Left Ventricular Mass Index as an independent predictor of major adverse cardiovascular and cerebrovascular events in patients with SLE.Lupus science & medicine · 2026Article
- Cardiac Complications in Systemic Lupus Erythematosus: A Systematic Review of Diagnostic and Prognostic Gaps.Cureus · 2026Review
- Metabolic and Vascular Inflammation in Alopecia Areata: Linking Uric Acid, Lipid Imbalance and ICAM-1 Upregulation.Experimental dermatology · 2025Article
- A novel approach to cardiovascular events in patients with systemic lupus erythematosus: risk factor assessment and treatment analysis.Rheumatology international · 2025Review
- Hemoperitoneum due to aneurysm rupture related to systemic lupus erythematosus: a case report.Journal of surgical case reports · 2025Article
- Levels of physical activity in a large international cohort of patients with systemic lupus erythematosus.Lupus science & medicine · 2025Article
- Impact of Sex on Infection Risk in Patients with Systemic Lupus Erythematosus.Bioengineering (Basel, Switzerland) · 2025Article
- Investigation of the cardiac impacts of endothelial PAS domain-containing protein 1 and ghrelin in patients with systemic lupus erythematosus.Revista da Associacao Medica Brasileira (1992) · 2025Article
- The immunomodulatory potential of vitamin D on Th17 lymphocytes in systemic lupus erythematosus - a literature review.Medicine and pharmacy reports · 2025Review
- The combination effect of treadmill exercise and valerian hydroalcoholic extract on the heart of type 2 diabetic rats.Annals of medicine and surgery (2012) · 2025Article
- Cutaneous Manifestations of Systemic Lupus Erythematosus and Their Correlation With Cardiac Involvement.Cureus · 2024Review
- Intestinal microbiome as a diagnostic marker of coronary artery disease: a systematic review and meta-analysis.Annals of medicine and surgery (2012) · 2024Review
- A novel case report of isolated cardiac myxedematosus.European heart journal. Case reports · 2024Article
- Article
- Update of Potential Biomarkers in Risk Prediction and Monitoring of Atherosclerosis in Systemic Lupus Erythematosus to Prevent Cardiovascular Disease.Biomedicines · 2023Review
- Causal relationship between PCSK9 inhibitor and autoimmune diseases: a drug target Mendelian randomization study.Arthritis research & therapy · 2023Article
- Increased carotid intima-media thickening and antioxidized low-density lipoprotein in an anti-Ro60 SLE autoantibody subset.Frontiers in lupus · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a condition in which autoimmune inflammation affects nearly every organ in the human body; it is characterized by a relapsing-remitting pattern. Systemic inflammation and tissue damage can arise from autoantibodies, the creation of immune complexes, and the deposition of autoantibodies, all defined as autoimmune diseases. Women of reproductive age are at a high risk of developing lupus, a chronic systemic condition. Among women between the ages of 15 and 44 years, the female-to-male ratio for the occurrence of lupus is as high as 13:1, while it is only 2:1 in children and in the elderly. In addition to accelerated atherosclerosis, SLE is associated with an increased risk of cardiovascular (CV) events such as coronary artery disease (CAD), peripheral artery disease (PAD), and cerebrovascular accident (CVA). Several SLE-specific processes, including impaired immunological regulation, impaired endothelial cell (EC) function, impaired vascular repair, hyperleptinemia, and traditional risk factors, contribute to early atherosclerosis in the disease. CAD can occur at any stage of the disease's progression, with younger individuals being much more at risk than their age-matched counterparts. This review article aims to provide a unique insight into the relationship between SLE and cardiovascular disease (CVD) by discussing the pathophysiological role of CVD in SLE, outlining screening criteria, and highlighting the treatment options for CVD in connection with SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.